A Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by American-European Congress of Ophthalmic Surgery
Sponsor:
Information provided by (Responsible Party):
American-European Congress of Ophthalmic Surgery
ClinicalTrials.gov Identifier:
NCT01459679
First received: September 19, 2011
Last updated: July 15, 2014
Last verified: July 2014
  Purpose

The objectives of this study are to evaluate and compare the safety and efficacy of three treatment regimens for corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System in impeding the progression of, and/or reducing maximum corneal curvature.


Condition Intervention Phase
Keratoconus
Corneal Ectasia
Device: KXL System (15 mW/cm2)
Device: KXL System (30 mW/cm2)
Device: KXL System (45 mW/cm2)
Drug: riboflavin ophthalmic solution
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery

Resource links provided by NLM:


Further study details as provided by American-European Congress of Ophthalmic Surgery:

Primary Outcome Measures:
  • Mean change in maximum corneal curvature (Kmax) from baseline [ Time Frame: Month 6 or 12 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Comparison of treatment groups within each treatment indication [ Time Frame: Month 6 and 12 ] [ Designated as safety issue: No ]

Estimated Enrollment: 4000
Study Start Date: July 2012
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: VibeX Treatment Group A
Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 8 minutes
Device: KXL System (15 mW/cm2)
UVA irradiation for 8 minutes at 15 mW/cm2
Drug: riboflavin ophthalmic solution
Drops of riboflavin ophthalmic solution will be applied in the eye every two minutes for 20 minutes
Other Name: VibeX
Active Comparator: VibeX Treatment Group B
Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 4 minutes
Device: KXL System (30 mW/cm2)
UVA irradiation for 4 minutes at 30 mW/cm2
Drug: riboflavin ophthalmic solution
Drops of riboflavin ophthalmic solution will be applied in the eye every two minutes for 20 minutes
Other Name: VibeX
Active Comparator: VibeX Treatment Group C
Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 2 minutes and 40 seconds
Device: KXL System (45 mW/cm2)
UVA irradiation for 2 minutes 40 seconds at 45 mW/cm2
Drug: riboflavin ophthalmic solution
Drops of riboflavin ophthalmic solution will be applied in the eye every two minutes for 20 minutes
Other Name: VibeX

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (all subjects):

  1. Be at least 12 years of age, male or female, of any race;
  2. Provide written informed consent and sign a HIPAA form. Patients who are under the age of 18 will need to sign an assent form as well as having a parent or legal guardian sign an informed consent;
  3. Willingness and ability to follow all instructions and comply with schedule for follow-up visits;
  4. For females capable of becoming pregnant, agree to have urine pregnancy testing performed prior to randomization of the study eye and on the day of the fellow eye treatment (which occurs between the 3 to 6 month study eye visits); must not be lactating, and must agree to use a medically acceptable form of birth control for at least one week prior to the randomization visit and continue to use the method until one month after the last dose of test article. Acceptable forms for birth control are spermicide with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal contraceptive, intrauterine device, or surgical sterilization of partner. For non-sexually active females, abstinence will be considered an acceptable form of birth control. Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (e.g. hysterectomy, bilateral tubal ligation, or bilateral oophorectomy);
  5. BSCVA of ≥1 letter and ≤80 letters on ETDRS chart;
  6. Presence of central or inferior steepening on the topographic map;
  7. Contact Lens Wearers Only: Removal of contact lenses is required for a 1 week period prior to the screening visit(s);
  8. Contact Lens Wearers Only: manifest refraction must be stable between two visits which occur at least 7 days apart. A stable refraction is one in which the manifest refraction spherical equivalent and the average K (Km) on the topographer taken at the first visit do not differ by more than 0.75 D from the respective measurements taken at the second exam;

    Inclusion Criteria (keratoconus subjects only):

  9. Have a maximum corneal curvature as measured by Kmax of ≥ 47.00 D;
  10. Having topographic evidence of keratoconus with a diagnosis of mild, moderate or severe keratoconus defined as the following:

    • Mild Keratoconus

      1. Axial topography consistent with keratoconus
      2. Flat keratometry reading ≤ 51.00 D on topography map
    • Moderate Keratoconus

      1. Axial topography consistent with keratoconus
      2. Flat keratometry reading ≥ 51.01 D and ≤ 56.00 D or astigmatism ≥ 8.00D on topography map
    • Severe Keratoconus:

      1. Axial topography consistent with keratoconus with marked areas of steepening
      2. Flat keratometry reading ≥ 56.01 D on topography map

    Inclusion Criteria (corneal ectasia subjects only):

  11. Having a diagnosis of corneal ectasia after refractive surgery;
  12. Having axial topography consistent with ectasia;

Exclusion Criteria (all subjects):

  1. Contraindications, sensitivity or known allergy to the test article(s) or their components;
  2. If female, be pregnant, nursing or planning a pregnancy or have a positive urine pregnancy test prior to the randomization or treatment of either eye or during the course of the study;
  3. Corneal pachymetry that is < 375 microns prior to epithelial debridement at the thinnest point in the eye to be treated;
  4. Eyes which are aphakic;
  5. Eyes which are pseudophakic and do not have a UV blocking lens implanted;
  6. Previous ocular condition (other than refractive error) in the eye to be treated that may predispose the eye for future complications. For example:

    1. History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.)
    2. Clinically significant corneal scarring in the cross-linking treatment zone that is not related to keratoconus or corneal ectasia, in the investigator's opinion, will interfere with the cross-linking procedure;
  7. A history of delayed epithelial healing in the eye(s) to be treated;
  8. Patients with nystagmus or any other condition that would prevent a steady gaze during the treatment or other diagnostic tests;
  9. Patients with a current condition that, in the investigator's opinion, would interfere with or prolong epithelial healing;
  10. Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking treatment.
  11. A history of previous corneal crosslinking treatment in the eye to be treated;
  12. Have used an investigational drug or device within 30 days of the study or be concurrently enrolled in another investigational drug or device trial within 30 days of the study;
  13. A history of previous corneal surgery (other than LASIK or PRK for subjects with corneal ectasia) or the insertion of Intacs in the eye(s) to be treated;
  14. A history of previous Limbal Relaxing Incision (LRI) procedure in the eye(s) to be treated;
  15. In addition, the Investigator may exclude or discontinue any subject for any sound medical reason;

    Exclusion Criteria (Keratoconus subjects only):

  16. Eyes classified as either normal, atypical normal, or keratoconus suspect on the severity grading scheme.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01459679

Contacts
Contact: Jennifer Mah 781-768-3475 jmah@avedro.com

  Show 83 Study Locations
Sponsors and Collaborators
American-European Congress of Ophthalmic Surgery
Investigators
Principal Investigator: John Vukich, MD American-European Congress of Ophthalmic Surgery
  More Information

No publications provided

Responsible Party: American-European Congress of Ophthalmic Surgery
ClinicalTrials.gov Identifier: NCT01459679     History of Changes
Other Study ID Numbers: ACOS-KXL-001
Study First Received: September 19, 2011
Last Updated: July 15, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Riboflavin
Dilatation, Pathologic
Keratoconus
Corneal Diseases
Pathological Conditions, Anatomical
Eye Diseases
Photosensitizing Agents
Radiation-Sensitizing Agents
Physiological Effects of Drugs
Pharmacologic Actions
Dermatologic Agents
Therapeutic Uses
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances

ClinicalTrials.gov processed this record on July 24, 2014